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Background. Gastrointestinal (GI) neuroendocrine tumor (NET) incidence has been increasing; however, GI NET within the
national Veterans Aﬀairs (VA) health system has not been described. Methods. We used the VA Central Cancer Registry to identify
the cohort of patients diagnosed with GI NET in 1995–2009. Cox regression models were constructed to explore factors associated
with survival. Results. We included 1793 patients with NET of the stomach (9%), duodenum (10%), small intestine (24%), colon
(19%) or rectum (38%). Twenty percent were diagnosed in 1995–1999, 35% in 2000–2004, and 45% in 2005–2009. Unadjusted 5-
year survival rates were: stomach 56%, duodenum 66%, small intestine 52%, colon 67%, and rectum 84%. Factors associated with
shorter survival were increasing age, hazard ratio (HR) 1.05 (95% CI 1.04–1.06), NET location [compared to rectum: stomach HR
2.26 (95% CI 1.68–3.05), duodenum HR 1.70 (95% CI 1.26–2.28), small intestine HR 1.85 (95% CI 1.42–2.42), and colon 1.83
(95% CI 1.41–2.39)], stage [compared to in situ/local: regional HR 1.15 (95% CI 0.90–1.47), distant HR 2.38 (95% CI 1.87–3.05)],
and earlier period of diagnosis [compared to 1995–1999: 2000–2004 HR 0.70 (95% CI 0.59–0.85), 2005–2009 HR 0.43 (95% CI
0.34–0.54)]. Conclusions. The incidence of GI NET has also increased over time in the VA system with similar survival rates to
those observed in non-VA settings. Worsened survival was associated with older age, tumor site, advanced stage, and earlier year
of diagnosis.
1.Introduction
Neuroendocrine tumors (NETs) arise from the embryologic
neuroendocrine system and thus can occur in any location
in the body. The gastrointestinal (GI) tract and lungs are the
most common primary tumor sites. Based on Surveillance
Epidemiology and End Results (SEER) data, NET incidence
has increased 300%, up to 5.3 per 100,000, in the last three
decades [1]. International data also suggest similar increases,
as more recent studies have observed higher incidences than
previous studies [2–4]. NET prevalence has also increased to
103,312 in the US population making it more prevalent than
adenocarcinoma of the stomach and pancreas combined
[1, 5]. Much of the apparent rise in new diagnoses may
reﬂect incidental detection of NET through the increased use
of imaging modalities such as computed tomography (CT)
scansandendoscopicproceduresforotherindicationsrather
than a true increase in tumor incidence. NETs are relatively
slow growing tumors usually diagnosed late in the clinical
course. Retrospective analysis suggests an average delay of
nine years between initial onset of symptoms and ﬁnal diag-
nosis [6]. Despite the long delay in diagnosis and advanced
stage of the disease, the 5-year survival rates are relatively
high which also contributes to the disease prevalence [7].
Based on autopsy data, the true prevalence may be closer to
65 to 120 in 100,000 [1, 8–10].2 Journal of Cancer Epidemiology
Most information regarding the epidemiology of NET
has been derived from the SEER database. Tumor location,
size, and histopathology and patient factors such as age, sex,
and race have previously been shown to predict survival [1,
9, 10] .W h i l et h i sd a t a b a s ei se x t e n s i v e ,i ti sl i m i t e dt oc e r t a i n
regions of the United States. In addition, heterogeneity of
patient populations and health care delivery systems could
confound some outcomes such as survival. The Veterans
Aﬀairs (VA) health system is the largest integrated health
system in the US and includes patients from allover the
country, and a single healthcare system may provide more
homogeneous data. Thus, the Veterans Aﬀairs (VA) popula-
tion provides an attractive alternative population in which
to examine NET characteristics and survival. In addition,
factors associated with the survival of patients in a large,
integrated system could be used to improve the care of
patients within that system. The purpose of this study is to
characterize patients with GI NET in the VA system and
explore factors associated with survival.
2. Methods
2.1.SettingandSample. Weconductedaretrospectivecohort
study of VA patients with a new diagnosis of GI NET as
identiﬁed in the VA Central Cancer Registry (CCR). Patients
in the VA CCR with a histological diagnosis of a primary
malignant GI neuroendocrine tumor between January 1995
and November 2009 were included in this study. There were
no exclusion criteria on the preliminary collection of data.
Some subjects were not included in all analyses because of
missing data. The cohort began with the year 1995 because
only 6 patients with GI NET were identiﬁed prior to 1995.
2.2. Data Sources. The VA CCR includes data from 143 VA
facilities across the United States. Case ascertainment at each
facility was accomplished by searching cytology, pathology,
and microscopic data for various specimens by histologic
codes,including neuroendocrine tumors.Inaddition, cancer
cases are ascertained by searching clinical data such as
radiology. Data for each cancer case were abstracted from
clinical records using standardized coding and uploaded to
the VA CCR every 6 months. The method of tissue diagnosis,
however, is not available in the administrative database [11].
Date of death was ascertained from the VA Vital Status
File.TheVitalStatusFileusesdatafromtheVeteransBeneﬁts
Administration’s (VBA) Beneﬁciary Identiﬁcation Records
LocatorsubsystemDeathFile(BIRLSDF),theSocialSecurity
Administration (SSA) DeathMaster File (DMF), the Medical
SAS Inpatient Datasets (MSID), and Medicare database to
determine a patient’s date of death. The cause of death was
not available; therefore, the study outcome was all-cause
death.Useofthesefoursourcestoascertaindeath(BIRLSDF,
MSID,SSADMF,andMedicare)wasshowntoidentify98.3%
of all National Death Index (NDI) deaths where NDI is
considered the gold standard for mortality data [12].
2.3.PredictorVariables. TheCCRdatabaseprovidedpatient-
level covariates: age, gender, race (which we collapsed into
white and nonwhite due to low numbers in some of the
nonwhite racial categories), marital status (married, not
married), and diagnosis date which we divided into 5-year
increments: 1995–1999, 2000–2004, and 2005–2009. Speciﬁc
tumor data were also obtained including primary tumor
location, tumor size, tumor extent (classiﬁed as localized,
regional, or distant), and treatment.
2.4. Statistical Analysis. Demographic and baseline clinical
characteristics were summarized using frequency and per-
cent for categorical characteristics, and means and standard
deviations for continuous descriptors. Unadjusted 5-year
survival rates from time of diagnosis by NET site were
estimated using the Kaplan-Meier method. Unadjusted and
adjusted hazardratio estimates and95% conﬁdenceintervals
were also generated using Cox proportional hazards models
where patients that were still alive on August 6, 2010 were
censored. We ran unadjusted models including each predic-
tor separately and then ran two multivariable survival mod-
els. Predictors we evaluated were age, race, marriage status,
tumor location, year of diagnosis, cancer stage, and tumor
size. In the ﬁrst adjusted model (Table 2,a d j u s t e dm o d e l1 ) ,
we included all predictors except for tumor size because of
the large number of patients missing tumor size data (n =
818). As a sensitivity analysis we also ran a multivariable
model removing cancer stage as we had about 170 missing a
tumor stage diagnosis (Table 2.A d j u s t e dM o d e l2 ) .T h ep r o -
portional hazards assumption was assessed for all covariates.
SAS, Version 9.2 (Cary, NC), was used for all analyses.
3. Results
From 1995 to 2009, there were 1855 patients diagnosed with
a primary NET of a digestive organ. We excluded 62 cases
that involved the pancreas (38), liver (19), anus (4), and
esophagus(1),becausetheincidencesofNETintheseorgans
were small. The remaining 1793 patients had been diagnosed
with NET of the stomach, duodenum, small intestine, colon
or rectum. The baseline characteristics of this cohort are
provided in Table 1. As is typical for a VA population, the
subjects were predominantly men, but there was racial diver-
sity. There were 35% non-white subjects, 98% of which were
African American. Table 1 lists NET characteristics for the
cohort.ThemostcommonGIsitewastherectum(38%)and
the small intestine (24%). The tumor size ranged from 1mm
to 280mm with a mean of 19.4mm. Most of the NETs were
diagnosed at an early stage, 62% in situ/local, but 12% had
distant metastasis at diagnosis. Among patients with metas-
tasis, the most common sites were liver (69%), unknown
(11%),peritoneum(9%),lung(5%),andlymphnodes(4%).
Sixty nine percent (69%) of patients with GI NETs
underwent tumor resection, 3% had unspeciﬁed surgery,
<1% had tumor destruction, and 0.1% (n = 2) were missing
information on treatment. In the resection group, there was
a negative margin rate of 61%, positive margins of 11%, and
28% with unknown margin status.
There was a steady increase in incidence over time. The
incidence increased by 256 cases between 1995–1999 and
2000–2004 time periods. The incidence increased furtherJournal of Cancer Epidemiology 3
Table 1: Demographic and baseline clinical characteristics of veterans with gastrointestinal neuroendocrine tumors (n = 1793).
Characteristic n (%) Deceased N = 647 Not deceased N = 1146
Age (years), mean (SD) 62.6 (11.0) 67.2 (11.1) 60.0 (10.0)
Gender
Male 1725 (96.3%) 635 (98.2%) 1090 (95.1%)
Female 67 (3.7%) 12 (1.9%) 55 (4.8%)
Race
White 1156 (65.5%) 452 (70.3%) 704 (62.8%)
Non-white 608 (34.5%) 191 (29.7%) 417 (37.2%)
Ethnicity
Hispanic 88 (4.9%) 22 (3.4%) 66 (5.8%)
Non-Hispanic 1705 (95.1%) 625 (96.6%) 1080 (94.2%)
Marital status
Married 893 (51.1%) 302 (48.6%) 591 (52.4%)
Not married 856 (48.9%) 319 (51.4%) 537 (48.6%)
GI NET location
Stomach 166 (9.3%) 71 (11.0%) 95 (8.3%)
Duodenum 186 (10.4%) 70 (10.8%) 116 (10.1%)
Small intestine 431 (24.0%) 229 (35.4%) 202 (17.6%)
Colon 336 (18.7%) 133 (20.6%) 203 (17.7%)
Rectum 674 (37.6%) 144 (22.3%) 530 (46.3%)
Cancer stage
In situ and localized 1106 (61.7%) 304 (47.0%) 802 (70.0%)
Regional 298 (16.6%) 131 (20.3%) 167 (14.6%)
Distant metastases 218 (12.2%) 136 (21.0%) 82 (7.2%)
Missing 171 (9.5%) 76 (11.8%) 95 (8.3%)
Tumor size (mm), mean (SD) 19.4 (26.4) 24.6 (31.8) 16.9 (23.0)
Treatment
Surgery 1309 (73.0%) 399 (61.7%) 910 (79.4%)
Radiation 21 (1.2%) 16 (2.5%) 5 (0.4%)
Chemotherapy 71 (4.0%) 45 (7.0%) 26 (2.3%)
Hormone 1(0.1%) 0 (0%) 1 (0.1%)
Biological response modiﬁers 26 (1.5%) 14 (2.2%) 12 (1.1%)
Year of diagnosis
1995–1999 363 (20.3%) 260 (40.2%) 103 (9.0%)
2000–2004 619 (34.5%) 262 (40.5%) 357 (31.2%)
2005–2009 811 (45.2%) 125 (19.3%) 686 (59.9%)
Missing data occurred as follows: gender (n = 1), race (n = 29), marital status (n = 44), tumor size (n = 818), surgery (n = 2), radiation (n = 5),
chemotherapy (n = 4), hormone (n = 5), and biological response modiﬁers (n = 1).
with an additional 192 cases between 2000–2004 and 2005–
2009 time periods. Thus, the largest percentage of cases
(45%) occurred during 2005–2009.
Unadjusted 5-year survival rates from time of diagnosis
by site were stomach 56%, duodenum 66%, small intestine
52%, colon 67%, and rectum 84%. In the unadjusted
model that included race, non-whites had decreased survival
compared to whites; however, in adjusted models, there
a r en or a c i a ld i ﬀerences (Table 2). Survival rates of patients
with a rectal tumor site were higher than each of the 4
othersitesinbothunadjustedandadjustedmodels(Table 2).
Increasing age, not being married, NET location [compared
torectum],stagecomparedtoinsitu/local,andearlierperiod
of diagnosis were associated with decreased survival in the
adjusted analysis. When cancer stage is removed from the
model, the magnitude of the hazard ratio for comparing
small intestine and colon to rectum is increased somewhat.
4. Discussion
This study provides the largest sample from a single health-
care system and represents a national sample of patients.
These data add to our knowledge of GI NET within the VA
by providing data on treatment and outcomes. This study
adds to our general knowledge of GI NET by providing
important information on survival trends and by conﬁrming4 Journal of Cancer Epidemiology
Table 2: Descriptives of demographic, clinical factors of survival and Cox regression model results.
Unadjusted Adjusted model 1 (n = 1721) Adjusted model 2 (n = 1721)
Characteristic Hazards ratio 95% CI Hazards ratio 95% CI Hazards ratio 95% CI
Age (years) 1.05 1.05-1.06 1.05 1.04–1.06 1.05 1.04-1.05
Race
White 1.00 (ref) — 1.00 (ref) — 1.00 (ref) —
Non-white 0.79 0.67–0.94 1.02 0.86–1.22 1.02 0.85–1.22
Marital status
Married 1.00 (ref) — 1.00 (ref) — 1.00 (ref) —
Not married 1.17 1.00–1.37 1.41 1.20–1.65 1.35 1.15–1.58
GI NET location
Rectum 1.00 (ref) — 1.00 (ref) — 1.00 (ref) —
Stomach 2.48 1.86–3.29 2.26 1.68–3.05 2.38 1.77–3.20
Duodenum 2.26 1.70–3.01 1.70 1.26–2.28 1.79 1.33–2.41
Small intestine 3.16 2.56–3.89 1.85 1.42–2.42 2.45 1.95–3.06
Colon 2.08 1.64–2.63 1.83 1.41–2.39 2.09 1.63–2.68
Year of diagnosis
1995–1999 1.00 (ref) — 1.00 (ref) — 1.00 (ref) —
2000–2004 0.64 0.54–0.77 0.70 0.59–0.85 0.70 0.58–0.85
2005–2009 0.36 0.28–0.45 0.43 0.34–0.54 0.41 0.32–0.52
Stage
In situ/localized 1.00 (ref) — 1.00 (ref) —
Regional 1.71 1.40–2.10 1.15 0.90–1.47
Distant 2.95 2.41–3.61 2.38 1.87–3.05
Missing 1.72 1.34–2.21 1.67 1.29–2.17
Tumor size (mm) 1.01 1.00-1.01 — —
previous results. We provide results from published studies
using SEER data as the context of what is currently known
about the survival of patients with GI NET; however, the
diﬀerent methods of collection between the databases do not
allow for direct comparisons of the data.
The incidences rates of the stomach, duodenum, small
intestine, colon, or rectum were comparable to the most
recent review of the SEER data [13]. The only potential
discrepancy involves the smaller incidence of pancreatic
NET (2%) compared to SEER data (11% of GI NET). The
reason remains unclear, but it may be that in the past,
the VA did not commonly document pancreatic NET as
suggested by the trend of more diagnosis in the latest 5-year
period. We did not include the pancreatic NET as well as
the liver, esophagus, and anus NET because of the smaller
incidences. The incidence rates of the other organs did,
however, correlate with new SEER data [13].
Our study shows a 223% increase in incidence GI NET
from the time period of 1995–1999 to 2005–2009. Our
adjusted analysis found an increased all-cause mortality rate
associated with older age, tumor site (compared to rectum),
and advanced cancer stage. As expected, those diagnosed in
earliertimeperiodshaveworsesurvivalthanthosediagnosed
in later time periods.
The increased GI NET incidence is consistent with previ-
ous SEER database analyses [1, 10, 13]. In part, this increase
is likely related to the increased use of endoscopy. The
VA, in particular, has had increased use of colonoscopy for
screening and surveillance [14]. Thus, there has been an
increased opportunity to incidentally diagnose colon and
rectal NET, and this may in part explain the higher percent-
age of rectal NET in this population (38%) compared to
the previous SEER database analysis which has also shown a
steady increase in rectal NET [9, 13, 15]. In addition, this VA
study cohort had a higher percentage non-white population
compared to the previous SEER data analysis by Modlin
et al. [9]. Blacks made up the majority of the 35% non-
white population in our study, and the Modlin study found
the black population to have 2.3 times more rectal NET per
population than whites [9].
The unadjusted 5-year survival rate was consistent with
previous SEER data, with the rectal NET having the highest
survival of 84% (versus 88% 1992–1999 SEER), followed
by duodenum at 66%, then small intestine with 52%
(1992–1999 SEER data with 63% but did not diﬀerentiate
between small bowel and duodenum), and colon with 67%
(versus 62% 1992–1999 SEER). Classically, rectal NETs have
been associated with better survival than NETs from other
locations, and this was observed in our population. The
better survival is likely due in part to increased incidental
diagnosis from endoscopic exams as previously noted. Also,
they may have earlier symptoms such as rectal bleeding that
would lead to further evaluation and subsequent diagnosis.
The older SEER analysis showed a small and often
nonstatistically signiﬁcant diﬀerence in survival between the
time period of 1973–1991 and 1992–1999, with an overall 5-
year survival of 59.5% and 67.2%, respectively [9]. Another
study compared the time period of 1973–1987 and 1988–
2004 and found a hazard ratio of 0.73 (95% CI 0.69 to
0.77) for 1988–2004 [1] .T h em o s tr e c e n tS E E Ra n a l y s i sJournal of Cancer Epidemiology 5
conﬁrms a trend of increasing 5-year survival in the last
30 years [13]. Our results suggest improved survival when
the diagnosis was made in 2005–2009 versus previous time
periods. Perhaps this was in part due to the increased inci-
dental ﬁndings through increased use of endoscopy and
radiographic imaging studies. Part of the improved survival
may also reﬂect that there was a longer period of observation
after a diagnosis resulting in an increased opportunity of
death during that time period.
Two-thirds of patients diagnosed with GI NET in the VA
system had local disease and 70% underwent resection or
tumor destruction. We found no diﬀerence in survival rates
betweenpatientswithlocaldiseaseascomparedtothosewith
regional. Although the distribution of stage at diagnosis (i.e.,
local, regional, and distant metastasis) was similar in this VA
population compared to the SEER database, the diﬀerences
in 5-year survival rates between stages appear attenuated.
Our results should be interpreted in the context of
the study’s strengths and limitations. VA databases provide
considerable linked data, and by examining patients in a
single health care system, there may be fewer confounders
to outcomes such as survival than in other databases. With
its many facilities distributed throughout the country, the
cohort we obtained provides a national sample of patients.
Admittedly, VA patients are a select population and thus may
not be generalizable to other populations. Interestingly and
contrary to popular belief, the VA patient life expectancy is
very similar to the general US population. A 2009 VA report
found that the life expectancy of male veterans was 75.6
years and 80.3 years for female veterans [16]. By comparison,
Central Intelligence Agency (CIA) data indicate that the
life expectancy of the general US population is 75.8 years
for men and 80.8 years for women [17]. There are also
limitations of cancer registries that include the observational
design, the lack of some clinical details that may also impact
survival such as comorbidity status, method of diagnosis
(e.g., incidental ﬁndings on endoscopy), and missing data
for some potentially important covariates (tumor size,
treatment). Also, we were not able to subtype the NETs into
categoriessuchasinsulinoma,gastrinoma,orVIPomawhich
limits our ability to understand the diﬀerent types of NET.
In conclusion, the incidence of GI NET has recently
increased in the VA population. Our ﬁndings indicate that
the incidence and prognosis of NETs in veterans are similar
to patients in non-VA settings. Since many patients with GI
NET have a good prognosis, future studies should examine
the role of surveillance after tumor resection or destruction.
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